An AI-Powered Blood Test to Detect Cancer Using NanoDSF

Brain cancers, such as gliomas, are very difficult to detect because of their localization and late onset of symptoms. Here, we have developed a novel cancer detection method based on plasma denaturation profiles obtained by a non-conventional use of Differential Scanning Fluorimetry. Using blood samples from glioma patients and healthy controls, we show that their denaturation profiles can be automatically distinguished with the help of machine learning algorithms with 92% accuracy. This promising approach can now be extended to other types of cancers and could become a powerful pan-cancer diagnostic and monitoring tool requiring only a simple blood test.

Abstract

Glioblastoma is the most frequent and aggressive primary brain tumor. Its diagnosis is based on resection or biopsy that could be especially difficult and dangerous in the case of deep location or patient comorbidities. Monitoring disease evolution and progression also requires repeated biopsies that are often not feasible. Therefore, there is an urgent need to develop biomarkers to diagnose and follow glioblastoma evolution in a minimally invasive way. In the present study, we described a novel cancer detection method based on plasma denaturation profiles obtained by a non-conventional use of differential scanning fluorimetry. Using blood samples from 84 glioma patients and 63 healthy controls, we showed that their denaturation profiles can be automatically distinguished with the help of machine learning algorithms with 92% accuracy. Proposed high throughput workflow can be applied to any type of cancer and could become a powerful pan-cancer diagnostic and monitoring tool requiring only a simple blood test.

View Full-Text

Keywords: glioma; biomarker; nanoDSF; diagnostic; liquid biopsy

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Tsvetkov, P.O.; Eyraud, R.; Ayache, S.; Bougaev, A.A.; Malesinski, S.; Benazha, H.; Gorokhova, S.; Buffat, C.; Dehais, C.; Sanson, M.; Bielle, F.; Figarella Branger, D.; Chinot, O.; Tabouret, E.; Devred, F. An AI-Powered Blood Test to Detect Cancer Using NanoDSF. Cancers 2021, 13, 1294. https://doi.org/10.3390/cancers13061294

AMA Style

Tsvetkov PO, Eyraud R, Ayache S, Bougaev AA, Malesinski S, Benazha H, Gorokhova S, Buffat C, Dehais C, Sanson M, Bielle F, Figarella Branger D, Chinot O, Tabouret E, Devred F. An AI-Powered Blood Test to Detect Cancer Using NanoDSF. Cancers. 2021; 13(6):1294. https://doi.org/10.3390/cancers13061294

Chicago/Turabian Style

Tsvetkov, Philipp O., Rémi Eyraud, Stéphane Ayache, Anton A. Bougaev, Soazig Malesinski, Hamed Benazha, Svetlana Gorokhova, Christophe Buffat, Caroline Dehais, Marc Sanson, Franck Bielle, Dominique Figarella Branger, Olivier Chinot, Emeline Tabouret, and François Devred. 2021. "An AI-Powered Blood Test to Detect Cancer Using NanoDSF" Cancers 13, no. 6: 1294. https://doi.org/10.3390/cancers13061294

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

An AI-Powered Blood Test to Detect Cancer Using NanoDSF

Simple Summary

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI